Basilea Pharmaceutica Ltd. is a Swiss-based biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies in the fields of oncology and anti-infectives. Founded in 2000 as a spin-out from a major pharmaceutical company, Basilea has established itself as a developer of novel small-molecule drugs aimed at addressing critical unmet medical needs. The company’s research strategies revolve around targeted drug design and optimization, leveraging proprietary screening platforms and collaborations with leading academic institutions.
In the anti-infective area, Basilea’s flagship products include Cresemba® (isavuconazole), an antifungal agent approved for the treatment of invasive aspergillosis and mucormycosis, and Zevtera®/Mabelio® (ceftobiprole), a broad-spectrum antibiotic indicated for hospital-acquired and community-acquired pneumonia. These products underline the company’s commitment to combating resistant pathogens and improving patient outcomes in serious infections. On the oncology front, Basilea’s pipeline features investigational kinase inhibitors targeting solid tumors and hematologic malignancies, with several candidates advancing through clinical trials.
Headquartered in Basel, Switzerland, Basilea maintains research and development sites in Europe and the United States, enabling it to support global clinical programs and regulatory filings across North America, Europe and Asia. The company has forged partnerships with regional distributors and leading pharmaceutical firms to facilitate market access and patient reach. Basilea also engages in licensing agreements to expand the geographic footprint of its marketed products and to co-develop late-stage assets.
Basilea is led by an executive management team with extensive experience in pharmaceutical R&D, regulatory affairs and commercial operations. Under the leadership of CEO Vania Rheden, the company continues to pursue a strategic agenda aimed at delivering differentiated therapies to healthcare providers and patients worldwide. Governing oversight is provided by a board of directors comprising industry experts in biotechnology, infectious diseases and corporate governance.
AI Generated. May Contain Errors.
